PAR · GNFT.PA
Genfit S.A.
€11.40-€0.06 (-0.52%)
Genfit S.A.’s quoted price sits in the upper half of its reported 52-week range, 26.36% below the high.
Loading market information…
NASDAQ · OSUR · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
OraSure Technologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.92% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
OraSure Technologies, Inc.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -$0.18. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow OraSure Technologies, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 7, 2025 | -$0.18-20.0% vs estimate | $29.93M+2.57% vs estimate |
|---|
| Q4 2024 | Feb 25, 2025 | -$0.14-180.0% vs estimate | $37.45M+1.74% vs estimate |
|---|
| Q3 2024 | Nov 6, 2024 | -$0.06-50.0% vs estimate | $39.92M+2.43% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
13 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $7.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€11.40-€0.06 (-0.52%)
Genfit S.A.’s quoted price sits in the upper half of its reported 52-week range, 26.36% below the high.
$3.14-$0.07 (-2.18%)
Nautilus Biotechnolgy, Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.15% below the high.
$18.98+$0.46 (+2.48%)
Prenetics Global Limited’s quoted price sits in the lower half of its reported 52-week range, 30.32% below the high.
$5.86+$0.08 (+1.38%)
Profound Medical Corp.’s quoted price sits in the lower half of its reported 52-week range, 34.53% below the high.
$66.80-$2.04 (-2.96%)
Utah Medical Products, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.12% below the high.
$2.38+$0.12 (+5.31%)
Neuronetics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 30.81% below the high.
$2.52+$0.03 (+1.2%)
Protara Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.77% below the high.
$1.17-$0.08 (-6.02%)
Perspective Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.01% below the high.
